Home > Insider Trading > Filing (0001209191-13-039044)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
816284	Celgene Corp	CELG	Pharmaceutical Preparations (2834)	222711928

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1260573	A Perry Karsen	C/O Celgene Corporation 86 Morris Avenue Summit NJ 07901	See Remarks	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2013-08-02	23,333	$59.50	23,789	No	4	M	Direct
Common Stock	Acquisiton	2013-08-02	69,675	$56.32	93,464	No	4	M	Direct
Common Stock	Acquisiton	2013-08-02	25,000	$0.00	118,464	No	4	M	Direct
Common Stock	Disposition	2013-08-02	12,962	$147.35	105,502	No	4	F	Direct
Common Stock	Disposition	2013-08-02	93,008	$146.50	12,494	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	F	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Unit	Disposition	2013-08-02	25,000	$0.00	25,000	$0.00
Common Stock	Stock Option (right to buy)	Disposition	2013-08-02	23,333	$0.00	23,333	$59.50
Common Stock	Stock Option (right to buy)	Disposition	2013-08-02	69,675	$0.00	69,675	$56.32

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		No	4	M	Direct
11,667	2020-12-27	No	4	M	Direct
0	2020-08-02	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	1,000	Indirect	IRA Account
Common Stock	614	Indirect	401(k) Plan

Footnotes

All of the restricted stock units granted to the reporting person on August 2, 2010 vested and settled for shares of the Company's common stock.
The price reported in Column 4 is a weighted average price. These shares were sold by the reporting person in multiple transactions at prices ranging from $145.63 to $148.06, inclusive. The reporting person undertakes to provide to Celgene Corporation (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
Each restricted stock unit represents a contingent right to receive one share of the Company's common stock.
The restricted stock units were issued pursuant to the Company's 2008 Incentive Plan (as amended).
The option was fully exercisable.
The option was issued pursuant to the Company's 2008 Stock Incentive Plan (as amended).